Discovery of Novel SHP2 ATTEC Degraders against Pancreatic Ductal Adenocarcinoma Harboring KRAS(G12D) Mutations
Journal of Medicinal Chemistry · 24.04.2025 · 68 (8) · 8143-8162
DOI: 10.1021/acs.jmedchem.4c02682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.04.2025. Verfasst von Yue Zhong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Government of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aberrant expression of the phosphatase SHP2 is implicated in numerous cancers, including KRAS G12D mutation driven PDAC. Although several SHP2 inhibitors have been reported, specific inhibitors with potent efficacy are not yet available. Given the elevated autophagy in PDAC, herein, we first designed novel SHP2 degraders through autophagosome-tethering compound strategy. Among them, the preferred 11n formed hydrogen bonds with Arg 111 and Glu 250 residues of SHP2 to enhance interactions between SHP2 and LC3. 11n also possessed great efficacy and selectivity against KRAS G12D mutant cancer cells versus the wild type. Moreover, the degradation caused by 11n manipulated the signaling pathways associated with cell apoptosis, metastasis, and invasion to inhibit the tumor growth both in vitro and in vivo. These findings not only generated a useful tool for exploring the potential of targeting SHP2 degradation but also offered promising candidates to develop novel drugs based on the autophagy mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China.
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24R Tongjiaxiang, Nanjing 210009, PR China.
ORCID-Profile: Hai Qian
Förderung
- Government of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Zhong, Y., Lu, Y., Li, J., Ren, Q., Fan, Y., Meng, X., Shao, J., & Qian, H. (2025). Discovery of Novel SHP2 ATTEC Degraders against Pancreatic Ductal Adenocarcinoma Harboring KRAS(G12D) Mutations. Journal of Medicinal Chemistry, 68(8), 8143-8162. https://doi.org/10.1021/acs.jmedchem.4c02682
Vancouver
Zhong Y, Lu Y, Li J, Ren Q, Fan Y, Meng X, et al. Discovery of Novel SHP2 ATTEC Degraders against Pancreatic Ductal Adenocarcinoma Harboring KRAS(G12D) Mutations. Journal of Medicinal Chemistry. 2025;68(8):8143-8162. doi:10.1021/acs.jmedchem.4c02682
BibTeX
@article{Zhong2025,
author = {Zhong, Yue and Lu, Yan and Li, Jiahui and Ren, Qiang and Fan, Yiqing and Meng, Xiqi and Shao, Jieyu and Qian, Hai},
title = {Discovery of Novel SHP2 ATTEC Degraders against Pancreatic Ductal Adenocarcinoma Harboring KRAS(G12D) Mutations},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {8},
pages = {8143--8162},
doi = {10.1021/acs.jmedchem.4c02682}
}
EUVIMED